Skip to content
HCN Grants Est. 2026
No. PAR-25-383 · National Institutes of Health
Open

Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)

Dealbreakers No cost share required
No audit required
“Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award.” — From the announcement
Reimbursement-only: not stated

At a glance

This program funds translational activities and clinical studies to advance therapeutic and diagnostic medical devices for disorders within the missions of participating NIH institutes and the HEAL and BRAIN Initiatives. It uses a two-phase UG3/UH3 cooperative agreement, with the UG3 supporting device development and regulatory preparation and the UH3 supporting a clinical study. Awards are not limited in budget, but the number of awards depends on NIH funds and the quality of applications, and the total project period may not exceed five years. Eligible applicants include nonprofits, universities, for-profit organizations, governments, tribal entities, faith-based and community-based organizations, and foreign organizations; foreign components and non-U.S. organizations are allowed. There is no cost-share requirement stated.

AI-generated summary — verify against the announcement

What it funds

  • Education
  • Health
  • Income Security and Social Services
  • Technology & Product Development
  • Other / needs-review
  • Biomedical & Disease Research
Official description from grants.gov

The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this NOFO or any of the companion opportunities. For more information see BP MedTech website.

Who can apply

  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities / Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Geographic restriction None found in the announcement — likely nationwide